News | March 25, 2014

Study Shows Heart Scans Not Always Useful in Prescribing Statins

statins, heart scan, CT scan

March 25, 2014 – As long as inexpensive statins, which lower cholesterol, are readily available and patients do not mind taking them, it does not make sense to do a heart comuted tomography (CT) scan to measure how much plaque has built up in a patient’s coronary arteries before prescribing the pills, according to a new study by researchers at UC San Francisco.

The researchers created a statistical model to predict whether or not it made sense to do the scan, using data from the Multi-Ethnic Study of Atherosclerosis and other sources. They modeled the effects of statin treatment in 10,000 55-year-old women with high cholesterol and a 10-year risk of coronary heart disease of 7.5 percent. The model predicted that giving statins to all of them would prevent 32 heart attacks, cause 70 cases of statin-induced muscle disease and add 1,108 years to their cumulative life expectancy.
 
Then, they looked at how a coronary artery calcium test, or CAC test, could be used to target statin therapy only to those women who the CAC test showed were at heightened risk of coronary heart disease. They found that this strategy would save money on statin costs and expose fewer women to side effects from statins but would not prevent as many heart attacks. Moreover, the test itself exposes the women to a small risk of radiation-induced cancer and costs about $200 to $400 per scan.
 
The researchers concluded that as long as the price of a statin remained low — 13 cents a pill — and did not reduce quality of life for patients, it was not cost-effective to perform a CAC test to target the drug therapy only toward those at increased risk of coronary heart disease. But if the price of the pill were more expensive — $1 or more — or if taking them reduced patients’ quality of life, then it did make sense to use the CAC test.
 
The result is somewhat surprising, given all the evidence that has accumulated over the last decade that the test strongly predicts heart attacks, said the lead author, Mark Pletcher, M.D., MPH, an associate professor of epidemiology and biostatistics, and medicine, at UCSF. The study was published online March 11, 2014, in Circulation: Cardiovascular Quality Outcomes.
 
Traditional prediction models, such as the Framingham-based risk equations, work imperfectly, and doctors have long sought better ways to figure out which patients would benefit most from taking statins, which can cause side effects, such as muscle aches, decreased cognitive function and cataracts.
 
“The prevailing wisdom is that if you have a test that predicts heart attacks, you should use it,” Pletcher said. “But even a test that is strongly predictive of future events, like a coronary artery calcium scan, does not itself improve outcomes. If it is used to keep some people off of statins that would otherwise take them, then fewer people will get protection from using statins, and more people will have heart attacks.”
 
The study incorporated data from MESA and many other sources to create a cost-effectiveness model. The researchers tested whether changing the other model inputs made a difference, and it turned out that the only critical factors were the cost of statins and the degree to which they decreased quality of life for patients.
 
Other authors on the paper include Michael Pignone, M.D., MPH, of the University of North Carolina, Chapel Hill; Stephanie Earnshaw, Ph.D., and Cheryl McDade, of RTI International, Research Triangle Park, North Carolina; Kathryn A. Phillips, Ph.D., of the UCSF Comprehensive Cancer Center and the UCSF Center for Translational and Policy Research on Personalized Medicine; Reto Auer, M.D., MAS, and Lydia Zablotska, M.D., Ph.D,. of the UCSF Department of Epidemiology and Biostatistics; and Philip Greenland, M.D., of the Northwestern University Feinberg School of Medicine.
 
The study was funded by the National Heart, Lung and Blood Institute, the National Cancer Institute and the Swiss National Science Foundation. The authors did not declare any conflicts of interest. 
 
For more information: circoutcomes.ahajournals.org

Related Content

ClariPi Gets FDA Clearance for AI-powered CT Image Denoising Solution
Technology | Computed Tomography (CT) | June 24, 2019
Artificial intelligence (AI) imaging solution form ClariPi Inc. has received U.S. Food and Drug Administration (FDA)...
Bay Labs Announces New Echocardiography Guidance Software Data at ASE 2019 Scientific Sessions
News | Cardiovascular Ultrasound | June 20, 2019
Bay Labs announced that new data on the company’s first-of-its-kind deep learning investigational guidance software...
Third FDA Clearance Announced for Zebra-Med's AI Solution for Brain Bleed Alerts
Technology | Artificial Intelligence | June 19, 2019
Zebra Medical Vision announced it has received its third U.S. Food and Drug Administration (FDA) 510(k) clearance for...
LVivo EF Comparable to MRI, Contrast Echo in Assessing Ejection Fraction
News | Cardiovascular Ultrasound | June 19, 2019
DiA Imaging Analysis announced the presentation of two studies assessing the performance and accuracy of the company's...
New Data Demonstrates Safety Profile of GammaTile Therapy for Various Brain Tumors
News | Brachytherapy Systems | June 18, 2019
GT Medical Technologies Inc. announced the presentation of clinical data from a prospective study of GammaTile Therapy...
Canon Medical Receives FDA Clearance for AiCE Reconstruction Technology for CT
Technology | Computed Tomography (CT) | June 18, 2019
Canon Medical Systems USA Inc. has received 510(k) clearance on its new deep convolutional neural network (DCNN) image...
Black Men Less Likely to Adopt Active Surveillance for Low-Risk Prostate Cancer
News | Prostate Cancer | June 17, 2019
A new study reveals black men are less likely than white men to adopt an active surveillance strategy for their...
International Working Group Releases New Multiple Myeloma Imaging Guidelines

X-ray images such as the one on the left fail to indicate many cases of advanced bone destruction caused by multiple myeloma, says the author of new guidelines on imaging for patients with myeloma and related disorders. Image courtesy of Roswell Park Comprehensive Cancer Center.

News | Computed Tomography (CT) | June 17, 2019
An International Myeloma Working Group (IMWG) has developed the first set of new recommendations in 10 years for...
Aidoc Earns FDA Approval for AI for C-spine Fractures
Technology | Artificial Intelligence | June 11, 2019
Radiology artificial intelligence (AI) provider Aidoc announced the U.S. Food and Drug Administration (FDA) has cleared...
SCCT Announces 2019 Gold Medal Award Recipients
News | Computed Tomography (CT) | June 05, 2019
The Society of Cardiovascular Computed Tomography (SCCT) will present the 2019 Gold Medal Award to Jonathon Leipsic, M....